
Opinion|Videos|April 18, 2025
Important Updates in the Management of Uncomplicated UTIs
Panelists discuss how American Urological Association (AUA) guidelines for recurrent uncomplicated urinary tract infections (UTIs) in women recommend culture-confirmed diagnosis, prophylactic antibiotics, nonantibiotic prevention, self-initiated treatment, and behavioral modifications while noting pivmecillinam’s recent FDA approval. Pivmecillinam features a penicillin-binding protein 2 inhibition mechanism with 85% to 95% efficacy against gram-negative uropathogens, including extended-spectrum β-lactamase producers; minimal intestinal flora disruption; low resistance rates; and primarily mild gastrointestinal adverse effects.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Summarize the current AUA guideline recommendations in managing recurrent uncomplicated UTIs in women.
- Pivmecillinam was recently FDA approved in April 2024. Briefly describe the mechanism of action of pivmecillinam and its clinical efficacy and safety profile.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
5






